Catalysts / SPTX
Upcoming FDA decisions and readouts we track for Seaport Therapeutics, each with the filing that announced it.
FreeBioList tracks 4 catalysts for Seaport Therapeutics (SPTX, listed on Nasdaq): 3 upcoming and 1 decided. They cover 2 programmes: GlyphAllo (Healthy volunteers (neuropsychiatric safety); Major depressive disorder) and GlyphAgo (Generalised anxiety disorder with sleep disturbance; Generalised anxiety disorder).
First on the list: the Phase 2B readout for GlyphAllo (Major depressive disorder), guided by the company to H1 2027. The furthest-out event tracked is Late 2028. By stage, the upcoming rows are 1 Phase 2A readout and 2 Phase 2B readouts.
Decided and on record:
Each outcome links to the filing or notice that reported it in the table below.
Of the 4 rows, 3 link to SEC filings (8-K or 6-K) and 1 to a company press release. 3 have been verified by a person reading the filing itself, most recently on 12 Sep 2026. 1 still needs confirming against the company's own filing. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Seaport Therapeutics SPTX · Nasdaq | GlyphAllo | Healthy volunteers (neuropsychiatric safety) | H2 2026 secondary source |
Phase 1 readout | Reported | Press release ↗ | No |
| Seaport Therapeutics SPTX · Nasdaq | GlyphAllo | Major depressive disorder | H1 2027 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Seaport Therapeutics SPTX · Nasdaq | GlyphAgo | Generalised anxiety disorder with sleep disturbance | Early 2028 company guidance |
Phase 2A readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Seaport Therapeutics SPTX · Nasdaq | GlyphAgo | Generalised anxiety disorder | Late 2028 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList